IO Biotech, Inc. (id:8414 IOBT)
3.00 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/24/2024 7:46:27 AM)
Exchange closed, opens in 1 hour 43 minutes
About IO Biotech, Inc.
Market Capitalization 56.67M
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
| Headquarters (address) |
Ole Maaløes Vej 3 Copenhagen 2200 Denmark |
| Phone | 45 70 70 29 80 |
| Website | https://www.iobiotech.com |
| Employees | 74 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | IOBT |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 3.00 - 2.10 |
| Market Capitalization | 56.67M |
| P/E trailing | 3.00 |
| P/E forward | 3.00 |
| Price/Book | 3.00 |
| Beta | 3.00 |
| EPS | -1.29 |
| EPS Denmark (ID:148, base:8) | 5.00 |